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a local microenvironment that favors the 
establishment of a vector-borne disease. For 
example, tick-derived saliva factors appear 
to inhibit inflammatory cytokine secretion 
thus preventing efficient immune responses 
against tick-borne Rickettsia (4); a defined 
molecule in the saliva of the Aedes aegypti 
mosquito (SAAG-4) has the potential to 
alter the Th-profile of the bite-induced 
immune response likely rendering the 
host unable to effectively eliminate vector-
borne viruses (5); and sand fly saliva has a 
caspase-dependent, pro-apoptotic effect on 
neutrophils resulting in an infection of the 
host with increased numbers of Leishmania 
parasites (6). Vector saliva can even exhibit 
its effect on the course of an infection when 
delivered separately from the infectious 
inoculum, as demonstrated by the injection 
of purified Plasmodium parasites followed 
by the bite of a non-infected mosquito and 
thus the delivery of salivary proteins in 
“trans” (7). Finally, even a temporal sepa-
ration of saliva- and pathogen-delivery can-
not eliminate effects of arthropod saliva on 
a subsequent infection with a vector-borne 
disease (8).
Numerous reports have documented the 
potent and pleiotropic effects of the saliva 
of blood-feeding arthropods, which include 
anti-coagulation, vasodilation anti-inflam-
mation [reviewed by (9)], calling into ques-
tion how minute amounts of proteins in the 
inoculum that is delivered during a blood 
meal could significantly alter the host’s 
immune response against the vector-deliv-
ered pathogen. This observation is particu-
larly puzzling considering that vector saliva 
primarily evolved to assist the arthropod in 
obtaining a blood meal and not to facilitate 
the infection of the vertebrate host with a 
vector-borne pathogen. The main effect of 
immunomodulatory saliva components in 
regard to infection appears to be temporary 
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Vector-borne pathogens are deposited into 
the skin of the vertebrate host animal dur-
ing the process of blood feeding. The patho-
gen establishes an infection from this site 
rather than by having direct access to the 
host’s circulatory system. In an attempt to 
simplify the complex interactions between 
multiple species (vertebrate host, arthro-
pod vector, and microbial pathogen) that 
occur during the blood meal and follow-
ing the deposition of pathogen in the host, 
researchers routinely use artificial animal 
models, which do not account for a num-
ber of potential parameters. The delivery 
of isolated, purified pathogens by injection 
rather than natural infection by pathogen-
carrying vectors introduces significant 
artifacts (1, 2). Therefore, insights gained 
from such models are somewhat limited 
and, not surprisingly, successes with experi-
mental vaccines developed by using those 
models have been very difficult to replicate 
in field trials. In addition to the route of 
delivery, the immune and disease-status of 
the vaccinee (e.g., chronic infection with 
parasitic organisms), the heterogeneity of 
the pathogen (i.e., exposure to different 
pathogen strains in the field compared to 
the challenge with a defined pathogen strain 
in the laboratory), an important difference 
between vector-borne pathogens delivered 
by needle and syringe after their isolation 
from an infected vector (artificial) and by 
an arthropod vector (natural) is the pres-
ence of arthropod saliva in the latter sce-
nario. The small amounts of vector-derived 
molecules in the infectious inoculum can 
significantly change the infectivity of the 
vector-borne pathogen as first described 
for Leishmania more than two decades ago 
(3). Saliva molecules delivered to the bite 
site together with a vector-borne pathogen 
have been shown to modulate or derail 
vertebrate immune responses resulting in 
and local, altering immune responses at the 
bite site in the skin long enough to allow 
the vector to feed and for small numbers of 
pathogenic organisms to establish an infec-
tion. In addition to these indirect effects, 
certain salivary proteins, such as Salp15 in 
ticks, can be used by the pathogen (Borrelia 
burgdorferi in this case) to directly protect 
it from antibody-mediated killing when 
the pathogen coats itself with the vector-
derived protein (10). These findings explain 
why only a small number of Plasmodium 
parasites injected by a mosquito and in the 
presence of arthropod saliva causes malaria 
infection, but large numbers of isolated 
(saliva-free) sporozoites have to be injected 
by needle and syringe to accomplish the 
same task. This is not only the case when 
injecting the parasites intravenously but 
also when infecting the host through the 
same route as the mosquito, the skin (11). 
Similar findings were made with Leishmania 
parasites, which efficiently establish infec-
tions after injection only when co-delivered 
with sand fly saliva (12). Observations such 
as these have prompted investigators to 
consider saliva proteins as vaccine candi-
dates based on the hypothesis that neutral-
izing these immunomodulatory molecules 
might eliminate their ability to provide 
an immunological cloak and allow innate 
immune responses in the vertebrate skin to 
successfully eliminate the small infectious 
inoculum. The idea is further supported 
by numerous reports going back several 
decades that the pre-exposure to saliva 
from certain vectors can induce protection 
against subsequent infectious bites. Using 
vector saliva rather than pathogen-derived 
antigens as vaccine candidates has a num-
ber of attractive advantages, including: (1) 
protective immunity might be independent 
of the pathogen strain; (2) vaccine efficacy 
might not be abrogated by escape mutants, 
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vaccines that target endogenous vector anti-
gens (e.g., the conserved protein subolesin 
(26), or the gut antigen Bm86 already used 
in the Australian veterinary tick vaccine 
TickGARD for two decades) and reduce the 
vector’s viability, fertility, or competence to 
transmit pathogens. Undoubtedly, combin-
ing antigens, either multiple vector-derived 
antigens, or antigens from pathogens and 
vectors will lead to more complicated and 
thus more expensive vaccines. However, the 
additive or potentially synergistic effect that 
may be created by targeting vector-borne 
pathogens at multiple levels carries the 
potential of finally having a significant 
impact on some of the most burdensome 
vector-borne diseases.
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